The UK and US have finalized a landmark trade agreement that will maintain no import taxes on UK pharmaceutical shipments entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to raise spending on drugs through the public health system. This move secures that duties on these vital products will be held at nothing for a period of 36 months.
This deal comes after recent warnings to significantly raise tariffs on patented pharmaceutical imports, with increases mentioned reaching double the cost.
"This deal with the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue equity to transatlantic medicine commerce," a statement noted.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's most significant goods shipped to the America, which is easily the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure made up nearly one-fifth of total UK exports in that timeframe.
"This agreement secures employment, stimulates capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key UK Commitments
The pact entails several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
The deal follows a ongoing row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by claims that American customers were charged several times more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or scrapped, while major investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the past decade.
